New Tests
NeoGenomics Announces the Launch of Biomarker Assist™ KRAS Single Gene Testing Program for Advanced or Metastatic NSCLC Patients Learn more
Catch Up with New and Enhanced Tests in All Methodologies
Innovation is one of NeoGenomics’ company values. We mean that literally – innovation is one of our Core Values – and we take it personally. We are continually refining and adding new assays in hereditary and somatic molecular genetics, IHC, FISH, flow cytometry, and cytogenetics to keep our test menu at the forefront of cancer diagnostics. To stay up-to-date with our latest news, please sign up for our newsletter here.
An Introduction to NeoGenomics' Diagnostic Services
Please Review Our List of Recently Launched Tests:
- KRAS (G12C) Mutation Analysis for NSCLC (4-23-2021)
- Melanoma Micromets (3-22-2021)
- Carcinoma Micromets (3-22-2021)
- Constitutional Chromosome Analysis (2-8-2021)
- HER2 Gastric/GEA (1-25-2021)
- HER2 Colorectal (1-25-2021)
- HER2 (Other) (1-25-2021)
- HER2 Colorectal (1-25-2021)
- HER2 (Other) (1-25-2021)
- HER2 Gastric/GEA (1-25-2021)
- NeoTYPE® Cholangiocarcinoma Profile (12-14-2020)
- Universal Solid Tumor NGS Fusion Panel (12-14-2020)
- Thyroid NGS Fusion Panel (12-14-2020)
- Targeted Solid Tumor NGS Fusion Panel (12-14-2020)
- Salivary Gland NGS Fusion Panel (12-14-2020)
- Colorectal NGS Fusion Panel (12-14-2020)
- Prostate NGS Fusion Panel (12-14-2020)
- Cholangio/Pancreatic Carcinoma NGS Fusion Panel (12-14-2020)
- Breast NGS Fusion Panel (12-14-2020)
- Brain NGS Fusion Panel (12-14-2020)
- PD-L1 22C3 FDA (KEYTRUDA®) for TNBC (Breast) (11-20-2020)
- Ki67 NET (10-22-2020)
- PIT1 (9-28-2020)
- Full Focus Cancer Panel (Germline) (9-23-2020)
- DLL3 (9-2-2020)
- NeoTYPE® Follicular Lymphoma Profile (8-4-2020)
- PDGFB Rearrangement (22q13) (7-13-2020)
- MYC Amplification for Angiosarcoma (7-13-2020)
- NeoLAB® Solid Tumor Liquid Biopsy (6-29-2020)
- InVisionFirst®-Lung Liquid Biopsy (6-29-2020)
- PIK3CA Mutation CDx - Plasma (6-25-2020)
- FGFR2 Rearrangement (6-15-2020)
- PRAME (5-25-2020)
- BRG1 (SMARCA4) (5-25-2020)
- PD-L1 28-8 FDA (OPDIVO® + YERVOY®) for NSCLC (5-25-2020)